TY - JOUR
T1 - COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission
AU - for the COVID-19 in diabetes in Austria study group
AU - Sourij, Harald
AU - Aziz, Faisal
AU - Bräuer, Alexander
AU - Ciardi, Christian
AU - Clodi, Martin
AU - Fasching, Peter
AU - Karolyi, Mario
AU - Kautzky-Willer, Alexandra
AU - Klammer, Carmen
AU - Malle, Oliver
AU - Oulhaj, Abderrahim
AU - Pawelka, Erich
AU - Peric, Slobodan
AU - Ress, Claudia
AU - Sourij, Caren
AU - Stechemesser, Lars
AU - Stingl, Harald
AU - Stulnig, Thomas
AU - Tripolt, Norbert
AU - Wagner, Michael
AU - Wolf, Peter
AU - Zitterl, Andreas
AU - Kaser, Susanne
N1 - Funding Information:
We would like to thank Kapsch Austria, Icomedias, and Microsoft Austria for programming the electronic case report form and the provision of secure data storage space. We thank Andrew Spencer for proofreading the manuscript. The study was supported by unrestricted research grants to the Austrian Diabetes Association from NovoNordisk, Novartis, Sanofi, AstraZeneca and Boehringer Ingelheim. The study funder was not involved in the design of the study; the collection, analysis and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.
Funding Information:
H. Sourij received unrestricted research grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, NovoNordisk and Sanofi; and received speaker's honoraria from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, MSD, NovoNordisk and Sanofi. SK received unrestricted research grants from Boehringer Ingelheim and MSD (CD Laboratory for Metabolic Crosstalk). SK received speaker's honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, NovoNordisk and Sanofi. CC received speaker's honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, NovoNordisk and Sanofi. H. Stingl received an unresctricted research grant from Boehringer Ingelheim; and received speaker's honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, NovoNordisk, Novartis, and Sanofi Aventis and Servier. CR received speaker's honoraria and congress support from AstraZeneca, NovoNordisk and Sanofi. All the other authors declare no conflicts of interest with regard to this manuscript.
Funding Information:
This study was supported by unrestricted research grants to the Austrian Diabetes Association from NovoNordisk, Novartis, Sanofi, AstraZeneca and Boehringer Ingelheim. Funding information
Funding Information:
We would like to thank Kapsch Austria, Icomedias, and Microsoft Austria for programming the electronic case report form and the provision of secure data storage space. We thank Andrew Spencer for proofreading the manuscript. The study was supported by unrestricted research grants to the Austrian Diabetes Association from NovoNordisk, Novartis, Sanofi, AstraZeneca and Boehringer Ingelheim. The study funder was not involved in the design of the study; the collection, analysis and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.
Publisher Copyright:
© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
PY - 2021/2
Y1 - 2021/2
N2 - Aim: To assess predictors of in-hospital mortality in people with prediabetes and diabetes hospitalized for COVID-19 infection and to develop a risk score for identifying those at the greatest risk of a fatal outcome. Materials and Methods: A combined prospective and retrospective, multicentre, cohort study was conducted at 10 sites in Austria in 247 people with diabetes or newly diagnosed prediabetes who were hospitalized with COVID-19. The primary outcome was in-hospital mortality and the predictor variables upon admission included clinical data, co-morbidities of diabetes or laboratory data. Logistic regression analyses were performed to identify significant predictors and to develop a risk score for in-hospital mortality. Results: The mean age of people hospitalized (n = 238) for COVID-19 was 71.1 ± 12.9 years, 63.6% were males, 75.6% had type 2 diabetes, 4.6% had type 1 diabetes and 19.8% had prediabetes. The mean duration of hospital stay was 18 ± 16 days, 23.9% required ventilation therapy and 24.4% died in the hospital. The mortality rate in people with diabetes was numerically higher (26.7%) compared with those with prediabetes (14.9%) but without statistical significance (P =.128). A score including age, arterial occlusive disease, C-reactive protein, estimated glomerular filtration rate and aspartate aminotransferase levels at admission predicted in-hospital mortality with a C-statistic of 0.889 (95% CI: 0.837-0.941) and calibration of 1.000 (P =.909). Conclusions: The in-hospital mortality for COVID-19 was high in people with diabetes but not significantly different to the risk in people with prediabetes. A risk score using five routinely available patient variables showed excellent predictive performance for assessing in-hospital mortality.
AB - Aim: To assess predictors of in-hospital mortality in people with prediabetes and diabetes hospitalized for COVID-19 infection and to develop a risk score for identifying those at the greatest risk of a fatal outcome. Materials and Methods: A combined prospective and retrospective, multicentre, cohort study was conducted at 10 sites in Austria in 247 people with diabetes or newly diagnosed prediabetes who were hospitalized with COVID-19. The primary outcome was in-hospital mortality and the predictor variables upon admission included clinical data, co-morbidities of diabetes or laboratory data. Logistic regression analyses were performed to identify significant predictors and to develop a risk score for in-hospital mortality. Results: The mean age of people hospitalized (n = 238) for COVID-19 was 71.1 ± 12.9 years, 63.6% were males, 75.6% had type 2 diabetes, 4.6% had type 1 diabetes and 19.8% had prediabetes. The mean duration of hospital stay was 18 ± 16 days, 23.9% required ventilation therapy and 24.4% died in the hospital. The mortality rate in people with diabetes was numerically higher (26.7%) compared with those with prediabetes (14.9%) but without statistical significance (P =.128). A score including age, arterial occlusive disease, C-reactive protein, estimated glomerular filtration rate and aspartate aminotransferase levels at admission predicted in-hospital mortality with a C-statistic of 0.889 (95% CI: 0.837-0.941) and calibration of 1.000 (P =.909). Conclusions: The in-hospital mortality for COVID-19 was high in people with diabetes but not significantly different to the risk in people with prediabetes. A risk score using five routinely available patient variables showed excellent predictive performance for assessing in-hospital mortality.
KW - coronavirus infection, diabetes, prediabetic state
UR - http://www.scopus.com/inward/record.url?scp=85097057528&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097057528&partnerID=8YFLogxK
U2 - 10.1111/dom.14256
DO - 10.1111/dom.14256
M3 - Article
C2 - 33200501
AN - SCOPUS:85097057528
SN - 1462-8902
VL - 23
SP - 589
EP - 598
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
IS - 2
ER -